Aventis abandons cariporide
Executive Summary
Aventis will not seek regulatory approval for cariporide, company says May 16. Phase III trial for cardiovascular drug candidate was halted in July 2002 by data safety monitoring board (1"The Pink Sheet" Feb. 24, p. 24)...
You may also be interested in...
Aventis Alvesco For Asthma Is One Of Five NDA/BLA Filings Planned For 2003
Aventis is planning a third quarter NDA filing for the asthma therapy Alvesco, one of up to five novel agents the company expects to reach the filing stage by early 2004
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.